Plethora Solutions Holdings
London
England
United Kingdom
11 articles about Plethora Solutions Holdings
-
Sciele Pharma, Inc. and Plethora Solutions Holdings Announce Positive Results of Final Phase III Pivotal Trial for PSD502 for Premature Ejaculation
7/29/2009
-
Plethora Solutions Holdings Sells Lead Drug Rights, Cuts Debt by 90%
5/26/2009
-
Sciele Pharma, Inc. And Plethora Solutions Holdings Announce That PSD502 Demonstrates Substantial Benefit in the Treatment of Premature Ejaculation
4/28/2009
-
Sciele Pharma, Inc. and Plethora Solutions Holdings Announce Completion of Patient Recruitment for Global Phase III Trial of PSD502 for Premature Ejaculation
2/18/2009
-
Sciele Pharma, Inc. and Plethora Solutions Holdings Announce Final Analysis of PSD502 for Premature Ejaculation; All Primary and Secondary Endpoints Met in Phase III Pivotal Trial
12/8/2008
-
Plethora Solutions Holdings Release: New Study Confirms the Role of ErecAid(R) as Supplemental First Line Treatment for Erectile Dysfunction
11/18/2008
-
Sciele Pharma, Inc. Announces That Plethora Solutions Holdings Has Completed European Phase III Trial of PSD502 for Premature Ejaculation
10/1/2008
-
Plethora Solutions Holdings and Paul Capital Healthcare Sign a $25M Revenue Interest Financing Agreement
4/1/2008
-
Sciele Pharma, Inc. Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation; Sciele to Purchase $7 Million Stake in Plethora
5/24/2007
-
Inyx, Inc. Signs Deal With Plethora Solutions Holdings To Produce Novel HFA Aerosol Indicated For The Treatment Of Premature Ejaculation For Clinical Trial In The United States
11/2/2006
-
Senetek PLC Licenses Invicorp(R) Erectile Dysfunction Treatment To Plethora Solutions Holdings For North America
2/21/2006